Keiko Arai

Summary

Affiliation: Teikyo University Institute of Medical Mycology
Country: Japan

Publications

  1. ncbi request reprint Short duration of diabetes and disuse of sulfonylurea have any association with insulin cessation of the patients with type 2 diabetes in a clinical setting in Japan (JDDM 30)
    Keiko Arai
    Arai Clinic, Yokohama 227 0044, Japan
    Endocr J 60:305-10. 2013
  2. doi request reprint Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus
    Keiko Arai
    Arai Clinic, Yokohama, Japan
    Diabetes Technol Ther 15:335-41. 2013
  3. doi request reprint The status of glycemic control by general practitioners and specialists for diabetes in Japan: a cross-sectional survey of 15,652 patients with diabetes mellitus
    Keiko Arai
    The Japanese Medical and Dental Practitioners for the Improvement of Medical Care, Tokyo, Japan
    Diabetes Res Clin Pract 83:397-401. 2009
  4. ncbi request reprint Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients
    Keiko Arai
    The Japanese Medical and Dental Practitioners for the Improvement of Medical Care, Tokyo, Japan
    Endocr J 57:499-507. 2010
  5. ncbi request reprint Association between body mass index and core components of metabolic syndrome in 1486 patients with type 1 diabetes mellitus in Japan (JDDM 13)
    Keiko Arai
    Arai Clinic, Aoba ku, Yokohama, Japan
    Endocr J 55:1025-32. 2008
  6. ncbi request reprint Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11)
    Koichi Hirao
    H E C Science Clinic, Yokohama, Japan
    Diabetes Res Clin Pract 79:171-6. 2008
  7. ncbi request reprint Both glimepiride and high-dose metformin are important for sustained glucose lowering in Japanese type 2 diabetes patients on glimepiride-sitagliptin-metformin therapy: subanalysis of a single-center, open-label, randomized study
    Keiko Arai
    1 Arai Clinic, Yokohama, Japan
    Diabetes Technol Ther 16:442-6. 2014

Detail Information

Publications8

  1. ncbi request reprint Short duration of diabetes and disuse of sulfonylurea have any association with insulin cessation of the patients with type 2 diabetes in a clinical setting in Japan (JDDM 30)
    Keiko Arai
    Arai Clinic, Yokohama 227 0044, Japan
    Endocr J 60:305-10. 2013
    ..Shorter duration of diabetes and disuse of sulfonylureas prior to insulin may associate with stopping insulin therapy as a near-normoglycemic remission in outpatients with T2DM in Japan...
  2. doi request reprint Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus
    Keiko Arai
    Arai Clinic, Yokohama, Japan
    Diabetes Technol Ther 15:335-41. 2013
    ..This study examined the impact of either a small dose of glimepiride or a high dose of metformin on HbA1c in triple OAD therapy with sitagliptin in a 3-month, single-center, open-label, randomized controlled study...
  3. doi request reprint The status of glycemic control by general practitioners and specialists for diabetes in Japan: a cross-sectional survey of 15,652 patients with diabetes mellitus
    Keiko Arai
    The Japanese Medical and Dental Practitioners for the Improvement of Medical Care, Tokyo, Japan
    Diabetes Res Clin Pract 83:397-401. 2009
    ..7%) than that by general practitioners (6.5%). This study showed that average HbA1c levels in Japanese patients treated by either general practitioners or specialists was acceptable, regardless of study limitations or bias...
  4. ncbi request reprint Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients
    Keiko Arai
    The Japanese Medical and Dental Practitioners for the Improvement of Medical Care, Tokyo, Japan
    Endocr J 57:499-507. 2010
    ..5%. In conclusion, the present study shows that sulfonylureas are central in the treatment of T2DM in Japan. However, careful consideration of suitable patients, agents, and doses is necessary to achieve appropriate glycemic control...
  5. ncbi request reprint Association between body mass index and core components of metabolic syndrome in 1486 patients with type 1 diabetes mellitus in Japan (JDDM 13)
    Keiko Arai
    Arai Clinic, Aoba ku, Yokohama, Japan
    Endocr J 55:1025-32. 2008
    ..For patients with T1DM, being overweight was associated with higher blood pressure and dyslipidemia. Furthermore, we cannot exclude an association between being overweight and the need for higher daily doses of insulin...
  6. ncbi request reprint Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11)
    Koichi Hirao
    H E C Science Clinic, Yokohama, Japan
    Diabetes Res Clin Pract 79:171-6. 2008
    ....
  7. ncbi request reprint Both glimepiride and high-dose metformin are important for sustained glucose lowering in Japanese type 2 diabetes patients on glimepiride-sitagliptin-metformin therapy: subanalysis of a single-center, open-label, randomized study
    Keiko Arai
    1 Arai Clinic, Yokohama, Japan
    Diabetes Technol Ther 16:442-6. 2014
    ..Conclusions: Together, the findings indicate that glimepiride and high-dose metformin are important for sustained glycemic control in triple OAD therapy with sitagliptin, metformin, and sulfonylurea. ..